 Zynerba Pharmaceuticals Inc NASDAQ:ZYNE, which works on innovative pharmaceutically produced transdermal cannabinoid therapies for neuropsychiatric disorders, posted results for the third quarter that revealed ample cash on hand, giving the company scope to fund pivotal trials of its flagship product Zygel ZYN002. As of September 30, 2022, the Devon, Pennsylvania-based company had cash and equivalents of 55.9 million, compared to 67.8 million at the end of December 2021. 